Search filters

List of works by Boen L Kam

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).

scientific article

Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate

scientific article published in October 2013

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

scientific article published on 16 January 2008

Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate ⬇️

scientific article published on July 23, 2013

Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?

scientific article published on 01 October 2006

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

scientific article

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

scientific article published on 13 August 2015

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

scientific article published on 10 May 2016

Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs ⬇️

scientific article published on December 1, 2012

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

scientific article

Peptide-receptor radionuclide therapy for endocrine tumors

scientific article published on 02 June 2009

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

scientific article published on 20 March 2017

Preclinical and clinical studies of peptide receptor radionuclide therapy

scientific article published on May 2010

Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate ⬇️

scientific article published on July 27, 2011

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

scientific article

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

scientific article

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

scientific article

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

scientific article published on 29 January 2010

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

scientific article published on 30 September 2015

Therapy-related hematological malignancies after peptide receptor radionuclide therapy with (177)Lu-DOTA-Octreotate: Incidence, course & predicting factors in patients with GEP-NETs

scientific article published on 03 August 2017

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy ⬇️

scientific article published on January 10, 2012

Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues

scientific article published on June 2007

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

scientific article published in May 2008

Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions ⬇️

scientific article published on July 10, 2012

Paulina is supported by:

About Paulina

Help